Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Comment by FormerSupporteron Dec 10, 2020 1:39pm
101 Views
Post# 32077903

RE:Science

RE:Science Thanks for your comment. I believe that ARDS is not the problem. It make a nice addition to the pipeline. The problem is the lack of focus and funds to make ARDS or any of thier early stage assets a success. They keep on jumping from prospect to prospect righ before they take it into the clinic. 

As mentioned I believe that ARDS, QIXLEEF and CAUMZS all have good potential but they are in the wrong hands. Tetra appears to be a discovery company. Find an early stage asset but no ability to develope it. This is almost completely due to the inability to raise sufficient money. The feeling with the old board was better not to dilute and never develope then take the risk. I hope the new directors are willing to get this company funded so that they can actually run a trial. 

Given the history, I'm not excited for the future.

 
<< Previous
Bullboard Posts
Next >>